BioStock: Great interest at conferences for Stayble’s treatment

Stayble Therapeutics has recently returned from the European Congress on Clinical Trials in Pain in Vienna where the progress in the clinical phase IIb study with STA363 for the treatment of degenerative disc disease was presented. During the autumn, the company has also participated in several partnering events, most recently BIO-Europe in Leipzig, to find potential partners for phase III. BioStock contacted the company’s CEO Andreas Gerward and CSO Anders Lehmann to get to know more about the interest in STA363 and their learnings from the events.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/12/great-interest-at-conferences-for-staybles-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se